Trials / Terminated
TerminatedNCT01009957
Everolimus on CKD Progression in ADPKD Patients
Everolimus on CKD (Chronic Kidney Disease) Progression in ADPKD Patients
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- A. Manzoni Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.
Detailed description
Considering the inhibitor activity of Everolimus on mTOR, our hypothesis is to evaluate its possible utility on the progression of CKD in ADPKD patients by reducing the rate of increase of renal cysts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | 0.75 mg x 2 / day |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2014-01-01
- Completion
- 2015-06-01
- First posted
- 2009-11-09
- Last updated
- 2015-06-23
Locations
7 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01009957. Inclusion in this directory is not an endorsement.